Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Tango Therapeutics, Inc. reported revenue of $62M, up 48.3% year over year. Operating margin was -178.4% and net margin -162.9%, on a free-cash-flow margin of -224.3% with capital expenditure at 1.7% of revenue. Every figure is computed directly from TNGX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $62M | -178.4% | -162.9% |
| FY2024 | $42M | -346.1% | -309.7% |
| FY2023 | $37M | -312.6% | -278.5% |
| FY2022 | $25M | -446.8% | -435.1% |
| FY2021 | $37M | -157.1% | -157.2% |
How does TNGX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.